Terozesta Tab

Tablet

Treatment of osteoporosis in postmenopausal women and men at high risk of fracture; glucocorticoid-induced osteoporosis at high risk of fracture; increases bone mass and reduces fracture risk in severe osteoporosis as prescribed.

Teriparatide is an anabolic (bone-building) agent. Intermittent administration stimulates osteoblast activity more than osteoclast activity, leading to new bone formation and increased bone mineral density, thereby lowering fracture risk.

Use exactly as prescribed by a doctor. Usually given as a once-daily subcutaneous injection; do not inject into a vein or muscle. Take adequate calcium and vitamin D as advised. If dizziness occurs after injection, sit/lie down; learn correct injection technique and safe needle disposal.

Nausea, dizziness, headache, leg cramps, injection site pain/redness, fatigue, transient increase in blood calcium

Prescription-only medicine. Not recommended in patients with hypercalcemia, severe kidney impairment, bone metastases or skeletal malignancy, Paget’s disease of bone, unexplained elevated alkaline phosphatase, prior radiation therapy involving the skeleton, or in children/young adults with open epiphyses. Use with caution in kidney stones/urolithiasis; monitor calcium if advised. Limit total duration of therapy as per prescribing information; follow-up for bone health is required. Seek urgent care for signs of allergic reaction, severe dizziness/fainting, or symptoms of high calcium.

Digoxin (risk of arrhythmias with hypercalcemia), calcium/vitamin D supplements (may increase hypercalcemia risk), thiazide diuretics (may increase calcium), other medicines affecting calcium or bone metabolism (as directed by physician).

Store refrigerated at 2–8°C. Do not freeze. Protect from light. Keep the container/pen capped; do not use if frozen or if solution is cloudy/has particles. Keep out of reach of children.

Forteo (Teriparatide), Terifrac (Teriparatide), Teriparatide injection (various brands)